# EDGAR Filing Document

**Accession Number:** 0001763950
**File Stem:** 0001493152-25-014652
**Filing Date:** 2025-9
**Character Count:** 5962
**Document Hash:** 7901691d8d8a28136afa6a8fdafff8e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-014652.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0001493152-25-014652

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250919

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250923

**DATE AS OF CHANGE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lantern Pharma Inc.
- **CENTRAL INDEX KEY:** 0001763950
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463973463
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39318
- **FILM NUMBER:** 251334267

**BUSINESS ADDRESS:**
- **STREET 1:** 1920 MCKINNEY AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75201
- **BUSINESS PHONE:** 972-277-1136

**MAIL ADDRESS:**
- **STREET 1:** 1920 MCKINNEY AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lantern Pharma
- **DATE OF NAME CHANGE:** 20190108

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 19, 2025

**<u>Lantern Pharma Inc.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39318** | **46-3973463** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **1920 McKinney Avenue, 7th Floor**<br> **Dallas, Texas** | **75201** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

(972) 277-1136

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value | LTRN | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On September 19, 2025, Lantern Pharma Inc. (the "Company") held its 2025 Annual Meeting of Stockholders, for the purposes of:

● Electing six directors, each to serve until our 2026 Annual Meeting of Stockholders;

● Approving the one-time repricing of certain stock options granted under the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended; and

● Ratifying the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

All of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop and David S. Silberstein, were elected to our board of directors, with shares voted as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **For** | **Withheld** | **Broker**<br> **Non-Vote** |
| **Donald Jeff Keyser** | 2213848 | 32958 | 5189274 |
| **Panna Sharma** | 2212199 | 34607 | 5189274 |
| **Vijay Chandru** | 2202401 | 44405 | 5189274 |
| **Maria Maccecchini** | 2214833 | 31973 | 5189274 |
| **Lee T. Schalop** | 2213670 | 33136 | 5189274 |
| **David S. Silberstein** | 2213088 | 33718 | 5189274 |

---

Our stockholders approved the one-time repricing of certain stock options granted under the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended, with shares voted as follows:

---

| | |
|:---|:---|
| **For** | 1458333 |
| **Against** | 758870 |
| **Abstain** | 29603 |
| **Broker Non-Votes** | 5189274 |

---

In addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025, with shares voted as follows:

---

| | |
|:---|:---|
| **For** | 7365922 |
| **Against** | 43732 |
| **Abstain** | 26426 |

---

There were no broker non-votes on the ratification of our independent registered public accounting firm.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Lantern Pharma Inc., | Lantern Pharma Inc., |
|  | A Delaware Corporation | A Delaware Corporation |
| Dated: September 23, 2025 | By: | */s/ David R. Margrave* |
|  |  | David R. Margrave, Chief Financial Officer |

---